Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1Classical hematology 1CNS 1

Conditions

Prostatic Neoplasms 1

Interventions

pembrolizumab 184Magnetic Resonance Spectroscopy 162Specimen Handling 134enzalutamide 125Nivolumab 118Gemcitabine 96Docetaxel 93Radiosurgery 91Prednisone 81Androgen Antagonists 80Abiraterone Acetate 79Radiotherapy 75apalutamide 66Cisplatin 65darolutamide 63Ipilimumab 61Biopsy 61abiraterone 58cabozantinib 55Carboplatin 55Leuprolide 52enfortumab vedotin 51Radiation 47Pluvicto 45Standard of Care 44atezolizumab 41Surveys and Questionnaires 38acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37X-Rays 37olaparib 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Quercetin × Genitourinary × 1 year × Clear all
NCT06615752 2026-04-15

Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients

Charles Drew University of Medicine and Science

Phase 1/2 Recruiting
99 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡